Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Introduction: Obesity is a global health challenge, and pharmacologic options are emerging. Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 analogue, has been shown to induce weight loss in clinical trials, but real-world effectiveness data are scarce. Methods: It is a single-centre retrospective cohort study of patients who were prescribed liraglutide on top of lifestyle adaptations after multidisciplinary evaluation. In Belgium, liraglutide is only indicated for weight management if the BMI is >30 kg/m 2 or ≥27 kg/m 2 with comorbidities such as dysglycaemia, dyslipidaemia, hypertension, or obstructive sleep apnoea. No indication is covered by the compulsory health care insurance. Liraglutide was started at 0.6 mg/day and uptitrated weekly until 3 mg/day or the maximum tolerated dose. Treatment status and body weight were evaluated at the 4-month routine visit. Results: Between June 2016 and January 2020, liraglutide was prescribed to 115 patients (77% female), with a median age of 47 (IQR 37.7–54.0) years, a median body weight of 98.4 (IQR 90.0–112.2) kg, a BMI of 34.8 (IQR 32.2–37.4) kg/m 2, and an HbA1c level of 5.6%. Five (4%) patients did not actually initiate treatment, 9 (8%) stopped treatment, and 8 (7%) were lost to follow-up. At the 4-month visit, the median body weight had decreased significantly by 9.2% to 90.8 (IQR 82.0–103.5) kg (p < 0.001). Patients using 3.0 mg/day (n = 60) had lost 8.0 (IQR 5.8–10.4) kg. The weight loss was similar (p = 0.9622) in patients that used a lower daily dose because of intolerance: 7.4 (IQR 6.2–9.6) kg for 1.2 mg (n = 3), 7.8 (IQR 4.1–7.8) kg for 1.8 mg (n = 16), and 9.0 (IQR 4.8–10.7) kg for 2.4 mg/day (n = 14). Weight loss was minimal if liraglutide treatment was not started or stopped prematurely (median 3.0 [IQR 0.3–4.8] kg, p < 0.001, vs. on treatment). Further analysis showed an additional weight reduction of 1.8 kg in the patients that had started metformin <3 months before the start of liraglutide (p < 0.001). The main reasons for liraglutide discontinuation were gastrointestinal complaints (n = 5/9) and drug cost (n = 2/9). Conclusion: In this selected group of patients, the majority complied with liraglutide treatment over the initial 4-month period and achieved a significant weight loss, irrespective of the maximally tolerated maintenance dose. Addition of metformin induced a small but significant additional weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, patients with type 2 diabetes were also represented in many studies51,53,54,56,57,59,62,63,65,68–71.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“The majority of RWS conducted in patients initiating incretin-based AOM were retrospective51–71 and included liraglutide users, while only a few studies investigated semaglutide titrated up to 2.4 mg65,66,69–71 (Tables 1 and 2).”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Morbidity and mortality associated with obesity
Abdelaal, M., le Roux, C. W., & Docherty, N. G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.107 · Cited by 1,052
Research works printed but not linked: 3
- 3. Durrer Schutz D, Busetto L, Dicker D, Far- pour-Lambert N, Pryke R, Toplak H, et al. Eu- ropean practical and patient-centred guide- lines for adult obesity management in prima- ry care. Obes Facts. 2019 Mar; 12(1): 40-66.
- 12. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese sub- jects treated for 2 years with orlistata random- ized controlled trial. JAMA. 1999 Jan; 281(3): 235-42.
- 24. Blackman A, Foster GD, Zammit G, Rosen- berg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep ap- nea: the scale sleep apnea randomized clinical trial. Int J Obes. 2016; 40(8): 1310-9.
Cited by
Current and novel treatment options for obstructive sleep apnoea
Randerath, W. J., de Lange, J., Hedner, J. A., Ho, J. T. F., Marklund, M., Schiza, S., Steier, J. S., & Verbraecken, J. A. (2022) · ERJ Open Research · doi:10.1183/23120541.00126-2022 · Cited by 100
Non-CPAP therapy for obstructive sleep apnoea
Verbraecken, J. A., Dieltjens, M., de Beeck, S. O., Vroegop, A. V. M. T., Braem, M. J. A., Vanderveken, O. M., & Randerath, W. J. (2022) · Breathe · doi:10.1183/20734735.0164-2022 · Cited by 83
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14940 · Cited by 40
“Recent real-world data studies have replicated the findings of previous GLP-1RA trials, with significant weight loss achieved, and the weight loss is similar across different doses.(17,18) This reinforces the importance of GLP-1RAs as an effective treatment for weight loss.”
ResultLiraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Obesity · doi:10.1002/oby.23752 · Cited by 27
“Recent real-world data studies have replicated the findings of the SCALE and STEP 1 trials, with significant weight loss achieved, and the weight loss was similar across different doses [17, 18].”
BackgroundRubio, M. Á., Carreiro, S. M., Sánchez-Pernaute, A., & Ramos-Levi, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102785 · Cited by 28
“Overall, the results have proven to be similar to real-world studies in patients who have not undergone prior bariatric surgery [20–22].”
ResultPharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
Pharmacological Treatments and Natural Biocompounds in Weight Management
Gasmi, A., Mujawdiya, P. K., Nehaoua, A., Shanaida, M., Semenova, Y. M., Piscopo, S., Menzel, A., Voloshyn, V., Voloshyn, O., Shanaida, V., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020212 · Cited by 24
“There is further information on significant weight loss in patients treated with Liraglutide during an initial 4-month period [47].”
BackgroundDai, C., & Zhu, W. (2022) · Medicine · doi:10.1097/md.0000000000031334 · Cited by 18
“Weight loss was significant even when the maximum daily dose was not reached.[19] However, despite a decrease in body weight and BMI in the normal weight T2DM group after treatment, the difference was not statistically significant.”
BackgroundValladales‐Restrepo, L. F., Sánchez-Ramírez, N., Usma-Valencia, A. F., Gaviria‐Mendoza, A., Machado‐Duque, M. E., & Machado‐Alba, J. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2178900 · Cited by 21
“The majority of patients reached the maximum doses for each drug, contrasting with other reports in which the proportion of those who reached this dose was lower [21,28,30,34].”
ResultVilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 28
Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice
Song, J.-E., Ko, H., & Kim, A. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s445415 · Cited by 25
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
“It is taken subcutaneously once daily at a dose of 3 mg and is prescribed in conjunction with a low-calorie diet plan and exercise to people with a BMI of ≥27 kg/m 2 or having weight-related complications [49,50].”
Jamal, M. H., Qasem, W., Hamshari, F., Dsouza, C. L., Alqallaf, N., Otiku, P., & Nnaji, C. A. (2023) · Obesity Science & Practice · doi:10.1002/osp4.706 · Cited by 16
“15 The tolerability of liraglutide was assessed with respect to the maximally tolerated dose.”
BackgroundAsiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03755-w · Cited by 23
Dobbie, L. J., Coelho, C., Mgaieth, F., Chauhan, K., Campbell, S., Shuriye, S., Hollington, J., Appleton, S., Sen Gupta, P., Duncan, A., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12649 · Cited by 12
Golden, A. K., & Davis, J. M. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s509971 · Cited by 11
Garvey, W. T., Cheng, M., Ramasamy, A., Smolarz, B. G., Park, S., Kumar, N., Kim, N., DerSarkissian, M., Bhak, R. H., Duh, M. S., et al. (2023) · Population Health Management · doi:10.1089/pop.2022.0227 · Cited by 9
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
“For now, insuf fi cient data limits its current clinical utility.”
Self-citationKushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5
Aladel, A., Aljaouni, J., & Basaad, R. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s417374 · Cited by 7
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Fitch, A. (2025) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2025.100621 · Cited by 3
Yskout, M., Steenackers, N., Hoste, J., Pazmiño, S., Simoens, C., Mattelaer, N., Deleus, E., Lannoo, M., Mertens, A. C., der Schueren, B. V., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01870-x · Cited by 5
Self-citationHepşen, S., Haymana, C., Helvacı, B. C., Durantaş, H., Torus, B., Çakmak, R., Güven, M., Demirci, İ., Keskin, L., Kiyici, S. K., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02836-5 · Cited by 4
“In this context, a study from Belgium analyzed weight loss with different doses of liraglutide and found that clinically meaningful weight loss can be achieved even when using submaximal doses [22].”
Effective Waste Management Strategies and Circularity of Plastics
Ramakrishna, S., & Ramasubramanian, B. (2024) · Springer eBooks · doi:10.1007/978-981-97-0589-4_4 · Cited by 3
Liraglutide - A Promising Approach Against Obesity
Rafi, N., Jaffri, M. S. A., & Yousuf, K. (2025) · Journal of Bahria University Medical and Dental College · doi:10.51985/jbumdc2024-455
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Use of liraglutide in the patient with obesity and type 2 diabetes mellitus: a literature review
Cancino, J. A. D., Álvarez, C. J. S., & Ramírez, K. A. Z. (2023) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20232577
Schirmer, M., Brandt, S., Zorn, S., & Wabitsch, M. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2079-9133 · Cited by 1
“[39] Trenson L, Trenson S, van Nes F et al.”
Efikasi Liraglutide Dalam Tatalaksana Obesitas Pada Pasien Dewasa Diabetik dan Non-Diabetik
Bramasta, A. A., & Novitasari, D. (2024) · Malahayati Nursing Journal · doi:10.33024/mnj.v6i2.12883
Lischka, J., Torbahn, G., Vallis, M., Mörwald, K., Gomahr, J., Forslund, A., Stenlid, R., Manell, H., Bergsten, P., Geiersberger, S., et al. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70122
“Escalation to the maximum dose may therefore not be necessary in all cases [44, 46, 47].”
Metadata
- Authors
- Trenson, L., Trenson, S., van Nes, F., Moyson, C., Lannoo, M., Deleus, E., Meulemans, A., Matthys, C., Mertens, A., Van der Schueren, B., & Vangoitsenhoven, R.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- AZ Sint-Jan (BE)
- ORCID
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2021-11-22
- Volume
- 15
- Issue
- 1
- Pages
- 83-89
- ISSN
- 1662-4025 (ISSN-L)
- 1662-4033
- PMC
- PMC8820228
- OpenAlex
- W3216600551
- Semantic Scholar
- 243ed3ed5076d329f6c4aa50e4cc2b0e6c91ac5c
- Cited by
- 34
- References
- 23
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 4
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Obesity Facts (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- KU Leuven
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- liraglutide, weight loss, obesity, GLP-1 receptor agonists, dose titration, real-world effectiveness, weight management, medication adherence, drug intolerance, lifestyle modification, body mass index, Belgium, health insurance coverage, treatment discontinuation, HbA1c, dyslipidemia, hypertension, obstructive sleep apnea
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.